Answers are grounded in this paper and cite their sources.
Policy analysis evaluates market dynamics of generic SGLT2 inhibitors, highlighting regulatory and economic strategies to maximize drug affordability.
Dr. Gondi reported employment at Health Strategy. Dr. Kesselheim and Dr. Rome reported receiving grants from the Elevance Health Public Policy Institute, Humana, and the PCMA Foundation and personal fees from Alosa Health outside the submitted work. Dr. Kesselheim also reports serving as an expert witness on behalf of a payor in a case against Teva regarding marketing of Copaxone and on behalf of a group of state attorneys general and payors in a case against multiple generic manufacturers related to alleged price fixing.
No takes yet. Share an insight, caveat, or question.
Gondi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: